Immune Unresponsiveness by Intraportal UV-B-Irradiated Donor Antigen Administration Requires Persistence of Donor Antigen in a Nerve Allograft Model

 

 Buy Article Permissions and Reprints

The purpose of this study was to characterize the mechanism of unresponsiveness produced by the intraportal administration of ultraviolet-B (UV-B)-irradiated donor antigen. Pretreated Buffalo rats accepted Lewis nerve allografts, had decreased in vitro T-cell reactivity, and demonstrated nerve regeneration and recovery of limb function, while rejecting third-party nerve allografts. Regenerated nerve grafts were then retransplanted into a second naïve recipient. Rejection of the retransplanted allograft by naïve donor-strain, but not recipient-strain, animals suggests that the allografts were completely replaced by host tissue. Pretreated Buffalo rats were also given a second Lewis allograft after the first had regenerated. The second allograft was rejected and in vitro immune reactivity was comparable to naïve animals. Because the unresponsiveness state was extinguished with loss of exposure to donor antigen, these findings suggest that the intraportal administration of UV-B-irradiated donor antigen works by anergic or suppressive regulatory, rather than deletional, mechanisms.

REFERENCES

• 1 Mackinnon S E, Hudson A R. Clinical application of peripheral nerve transplantation.  Plast Reconstr Surg. 1992;  90 696-699
  PubMedGoogle Scholar
• 2 Mackinnon S E. Nerve allotransplantation following severe tibial nerve injury-a case report.  Neurosurgery. 1996;  84 671-676
  PubMedGoogle Scholar
• 3 Mackinnon S E, Doolabh V B, Novak C B, Trulock E P. Clinical outcome following nerve allograft transplantation.  Plast Reconstr Surg. 2001;  107 1419-1429
  CrossrefPubMedGoogle Scholar
• 4 Bain J R, Mackinnon S E, Hudson A R, et al.. The peripheral nerve allograft: an assessment of regeneration across nerve allografts in rats immunosuppressed with Cyclosporin A.  Plast Reconstr Surg. 1988;  82 1052-1064
  PubMedGoogle Scholar
• 5 Brenner M J, Tung T H, Jensen J N, Mackinnon S E. The spectrum of complications of immunosuppression: is the time right for hand transplantation?.  J Bone Joint Surg. 2002;  84A 1861-1870
  PubMedGoogle Scholar
• 6 Genden E M, Mackinnon S E, Yu S, et al.. Pretreatment with portal venous ultraviolet B-irradiated donor alloantigen promotes donor-specific tolerance to rat nerve allografts.  Laryngoscope. 2001;  111 439-447
  PubMedGoogle Scholar
• 7 Midha R, Mackinnon S E, Evan P J. Comparison of regeneration across nerve allografts with temporary or continuous CsA immunosuppression.  J Neurosurg. 1993;  78 90-100
  CrossrefPubMedGoogle Scholar
• 8 Midha R, Mackinnon S E, Becker L E. The fate of Schwann cells in peripheral nerve allografts.  Neuropath Exp Neurol. 1994;  53 316
  PubMedGoogle Scholar
• 9 Grochowicz P, Romanuik A, Jedrzejewska A, Olszewski W L. Rejection pattern of nerve allografts-changes in graft and host cell determinants.  Transplant Proc. 1987;  19 1131-1132
  PubMedGoogle Scholar
• 10 Atchabahian A, Doolabh V, Mackinnon S E, et al.. Indefinite survival of peripheral nerve allografts after temporary Cyclosporin A immunosuppression.  Restor Neurol Neurosci. 1998;  13 129-139
  PubMedGoogle Scholar
• 11 Midha R, Evan P J, Mackinnon S E, Wade J A. Temporary immunosuppression for peripheral nerve allograft.  Transplant Proc. 1993;  25 532-536
  PubMedGoogle Scholar
• 12 Atchabahian A, Genden E M, Mackinnon S E, et al.. Regeneration through long nerve grafts in the swine model.  Microsurgery. 1998;  18 379-382
  CrossrefPubMedGoogle Scholar
• 13 Tung T H, Mackinnon S E, Mohanakumar T. Long-term limb allograft survival using anti-CD40L antibody in a murine model.  Transplantation. 2003;  75 644-650
  PubMedGoogle Scholar
• 14 Callery M P, Kamei T, Flye M W. Kupffer cell blockade inhibits induction of tolerance by the portal venous route.  Transplantation. 1989;  47 1092-1094
  PubMedGoogle Scholar
• 15 Chase M W. Inhibition of experimental drug allergy by prior feeding of the sensitizing agents.  Proc Soc Exp Biol. 1946;  91 226
  PubMedGoogle Scholar
• 16 Kripke M L. Effects of UV radiation on tumor immunity.  J Natl Cancer Inst. 1990;  82 1392-1396
  PubMedGoogle Scholar
• 17 Yu S, Nakafusa Y, Flye M W. Portal vein administration of donor cells promotes peripheral allospecific hyporesponsiveness and graft tolerance.  Surgery. 1994;  116 229-234
  PubMedGoogle Scholar
• 18 Simon J C, Tigelaar R E, Bergstresser R. Ultraviolet B irradiation converts Langerhans cells from immunogenic to tolerogenic antigen presenting cells: induction of specific clonal anergy in CD4⁺ T helper-1 cells.  J Immunol. 1991;  146 485-491
  PubMedGoogle Scholar
• 19 Dong V M, Womer K L, Sayegh M H. Transplantation tolerance: the concept and its applicability.  Pediatric Transplantation. 1999;  3 181-192
  CrossrefPubMedGoogle Scholar
• 20 Gudmundsdottir H, Turka L A. Transplantation tolerance: mechanisms and strategies?.  Sem Nephrol. 2000;  20 209-216
  PubMedGoogle Scholar
• 21 Aradhye S, Turka L A. Will tolerance become a clinical reality?.  Am J Med Sci. 1997;  313 310-314
  PubMedGoogle Scholar
• 22 Khan A, Tomita Y, Sykes M. Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen.  Transplantation. 1996;  62 380-387
  PubMedGoogle Scholar
• 23 Morecki S, Leshem B, Eid A, Slavin S. Alloantigen persistence in induction and maintenance of transplantation tolerance.  J Exp Med. 1987;  165 1468-1480
  CrossrefPubMedGoogle Scholar
• 24 Ramsdell F, Fowlkes B J. Maintenance of in vivo tolerance by persistence of antigen.  Science. 1992;  257 1130-1134
  PubMedGoogle Scholar
• 25 Kripke M L. Ultraviolet radiation and immunology: something new under the sun-presidential address.  Cancer Research. 1994;  54 6102-6105
  PubMedGoogle Scholar

Susan E MackinnonM.D. 

Division of Plastic and Reconstructive Surgery, Department of Surgery

Suite 5401, 660 South Euclid Ave.

St. Louis, MO 63110